{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T07:32:57Z","timestamp":1740123177101,"version":"3.37.3"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1-2","license":[{"start":{"date-parts":[[2016,2,23]],"date-time":"2016-02-23T00:00:00Z","timestamp":1456185600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001501","name":"University Grants Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001501","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cell Biochem"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1007\/s11010-016-2661-x","type":"journal-article","created":{"date-parts":[[2016,2,23]],"date-time":"2016-02-23T09:50:48Z","timestamp":1456221048000},"page":"85-94","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Modulation of PBMC-decay accelerating factor (PBMC-DAF) and cytokines in rheumatoid arthritis"],"prefix":"10.1007","volume":"414","author":[{"given":"Roma","family":"Pahwa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uma","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nibhriti","family":"Das","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,2,23]]},"reference":[{"key":"2661_CR1","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1196\/annals.1351.019","volume":"1069","author":"TK Kvien","year":"2006","unstructured":"Kvien TK, Uhlig T, \u00d8degard S, Heiberg MS (2006) Epidemiological aspects of rheumatoid arthritis: the sex ratio. Ann N Y Acad Sci 1069:212\u2013222","journal-title":"Ann N Y Acad Sci"},{"key":"2661_CR2","doi-asserted-by":"crossref","first-page":"3831","DOI":"10.4049\/jimmunol.1203487","volume":"190","author":"D Ricklin","year":"2013","unstructured":"Ricklin D, Lambris JD (2013) Complement in immune and inflammatory disorders: pathophysiological mechanisms. J Immunol 190:3831\u20133838","journal-title":"J Immunol"},{"key":"2661_CR3","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.clim.2005.10.014","volume":"118","author":"DD Kim","year":"2006","unstructured":"Kim DD, Song WC (2006) Membrane complement regulatory proteins. Clin Immunol 118:127\u2013136","journal-title":"Clin Immunol"},{"key":"2661_CR4","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/nri2620","volume":"9","author":"P Zipfel","year":"2009","unstructured":"Zipfel P, Skerka C (2009) Complement regulators and inhibitory proteins. Nat Rev Immunol 9:729\u2013740","journal-title":"Nat Rev Immunol"},{"key":"2661_CR5","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.1002\/art.20478","volume":"50","author":"AS Williams","year":"2004","unstructured":"Williams AS, Mizuno M, Richards PJ, Holt DS, Morgan BP (2004) Deletion of the gene encoding CD59a in mice increases disease severity in a murine model of rheumatoid arthritis. Arthritis Rheum 50:3035\u20133044","journal-title":"Arthritis Rheum"},{"key":"2661_CR6","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.molimm.2004.03.004","volume":"41","author":"V Arora","year":"2004","unstructured":"Arora V, Verma J, Dutta R, Marwah V, Kumar A, Das N (2004) Reduced complement receptor 1 (CR1, CD35) transcription in systemic lupus erythematosus. Mol Immunol 41:449\u2013456","journal-title":"Mol Immunol"},{"key":"2661_CR7","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1177\/0961203311434104","volume":"21","author":"B Biswas","year":"2012","unstructured":"Biswas B, Kumar U, Das N (2012) Expression and significance of leukocyte membrane cofactor protein transcript in systemic lupus erythematosus. Lupus 21:517\u2013525","journal-title":"Lupus"},{"key":"2661_CR8","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1084\/jem.165.3.848","volume":"165","author":"ME Medof","year":"1987","unstructured":"Medof ME, Walter EI, Rutgers JL, Knowles DM, Nussenzweig V (1987) Identification of the complement decay-accelerating factor (DAF) on epithelium and glandular cells and in body fluids. J Exp Med 165:848\u2013864","journal-title":"J Exp Med"},{"key":"2661_CR9","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.4049\/jimmunol.177.2.1070","volume":"177","author":"M Capasso","year":"2006","unstructured":"Capasso M, Durrant LG, Stacey M, Gordon S, Ramage J, Spendlove l (2006) Co stimulation via CD55 on human CD4\u00a0+\u00a0T cells mediated by CD97. J Immunol 177:1070\u20131077","journal-title":"J Immunol"},{"key":"2661_CR10","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1084\/jem.20041967","volume":"201","author":"PS Heeger","year":"2005","unstructured":"Heeger PS, Lalli PN, Lin F, Valujskikh A, Liu J, Muqim N et al (2005) Decay accelerating factor modulates induction of T cell immunity. J Exp Med 201:1523\u20131530","journal-title":"J Exp Med"},{"key":"2661_CR11","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/S0002-9440(10)64268-X","volume":"161","author":"T Miwa","year":"2002","unstructured":"Miwa T, Maldonado MA, Zhou L, Sun X, Luo HY, Cai D et al (2002) Deletion of decay-accelerating factor (CD55) exacerbates auto-immune disease development in MRL\/lpr mice. Am J Pathol 161:1077\u20131086","journal-title":"Am J Pathol"},{"key":"2661_CR12","first-page":"12","volume":"452853","author":"CB Toomey","year":"2014","unstructured":"Toomey CB, Cauvi DM, Pollard KM (2014) The role of decay accelerating factor in environmentally induced and idiopathic systemic autoimmune disease. Autoimmune Dis 452853:12. doi: 10.1155\/2014\/452853","journal-title":"Autoimmune Dis"},{"key":"2661_CR13","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1002\/art.27347","volume":"62","author":"RM Hoek","year":"2010","unstructured":"Hoek RM, de Launay D, Kop EN, Yilmaz-Elis AS, Lin F, Reedquist KA et al (2010) Deletion of either CD55 or CD97 ameliorates arthritis in mouse models. Arthritis Rheum 62:1036\u20131042","journal-title":"Arthritis Rheum"},{"key":"2661_CR14","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s13075-015-0518-4","volume":"17","author":"ON Karpus","year":"2015","unstructured":"Karpus ON, Kiener HP, Niederreiter B, Yilmaz-Elis AS, van der Kaa J, Ramaglia V et al (2015) CD55 deposited on synovial collagen fibers protects from immune complex-mediated arthritis. Arthritis Res Ther 17:6. doi: 10.1186\/s13075-015-0518-4","journal-title":"Arthritis Res Ther"},{"key":"2661_CR15","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1093\/rheumatology\/33.8.707","volume":"33","author":"J Jones","year":"1994","unstructured":"Jones J, Laffafian I, Cooper AM, Williams BD, Morgan BP (1994) Expression of complement regulatory molecules and other surface markers on neutrophils from synovial fluid and blood of patients with rheumatoid arthritis. Br J Rheumatol 33:707\u2013712","journal-title":"Br J Rheumatol"},{"key":"2661_CR16","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1046\/j.1365-2249.1998.00449.x","volume":"111","author":"M Arora","year":"1998","unstructured":"Arora M, Kumar A, Das SN, Srivastava LM (1998) Complement-regulatory protein expression and activation of complement cascade on erythrocytes from patients with rheumatoid arthritis (RA). Clin Exp Immunol 111:102\u2013106","journal-title":"Clin Exp Immunol"},{"key":"2661_CR17","first-page":"193","volume":"9","author":"M Fattouh","year":"2013","unstructured":"Fattouh M, Mohamed T, A Fadl ME, Hafez AR (2013) A flowcytometry study of complement regulatory proteins expression on peripheral blood cells in rheumatoid arthritis patients. J Am Sci 9:193\u2013201","journal-title":"J Am Sci"},{"key":"2661_CR18","first-page":"366","volume":"3","author":"CK Edwards","year":"2012","unstructured":"Edwards CK, Green JS, Volk HD, Schiff M, Kotzin BL, Mitsuya H et al (2012) Combined anti-tumor necrosis factor-\u03b1 therapy and DMARD therapy in rheumatoid arthritis patients reduces inflammatory gene expression in whole blood compared to DMARD therapy alone. Front Immunol 3:366\u2013370","journal-title":"Front Immunol"},{"key":"2661_CR19","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/j.1365-2249.1996.tb08288.x","volume":"103","author":"A Bucht","year":"1996","unstructured":"Bucht A, Larsson P, Weisbrot L, Thorne C, Pisa P, Smedeg\u00e5rd G, Keystone EC, Gr\u00f6nberg A (1996) Expression of interferon-gamma (IFN-gamma), IL-10, IL-12 and transforming growth factor-beta (TGF-beta) mRNA in synovial fluid cells from patients in the early and late phases of rheumatoid arthritis (RA). Clin Exp Immunol 103:357\u2013367","journal-title":"Clin Exp Immunol"},{"key":"2661_CR20","doi-asserted-by":"crossref","first-page":"327","DOI":"10.18388\/abp.2010_2412","volume":"57","author":"S Tukaj","year":"2010","unstructured":"Tukaj S, Kotlarz A, Jozwik A, Smolenska Z, Bryl E, Witkowski JM et al (2010) Cytokines of the Th1 and Th2 type in sera of rheumatoid arthritis patients; correlations with anti-Hsp40 immune response and diagnostic markers. Acta Biochim Pol 57:327\u2013332","journal-title":"Acta Biochim Pol"},{"key":"2661_CR21","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.clinbiochem.2010.07.012","volume":"43","author":"N Milman","year":"2010","unstructured":"Milman N, Karsh J, Booth RA (2010) Correlation of a multi-cytokine panel with clinical disease activity in patients with rheumatoid arthritis. Clin Biochem 43:1309\u20131314","journal-title":"Clin Biochem"},{"key":"2661_CR22","doi-asserted-by":"crossref","first-page":"e60900","DOI":"10.1371\/journal.pone.0060900","volume":"8","author":"J Lee","year":"2013","unstructured":"Lee J, Lee J, Park M-K, Lim MA, Park EM (2013) Interferon gamma suppresses collagen-induced arthritis by regulation of Th17 through the induction of indoleamine-2, 3-deoxygenase. PLoS ONE 8:e60900","journal-title":"PLoS ONE"},{"key":"2661_CR23","doi-asserted-by":"crossref","first-page":"329","DOI":"10.4049\/jimmunol.181.1.329","volume":"181","author":"PD Doodes","year":"2008","unstructured":"Doodes PD, Cao Y, Hamel KM, Wang Y, Farkas B, Iwakura Y, Finnegan A (2008) Development of proteoglycan-induced arthritis is independent of IL-17. J Immunol 181:329\u2013337","journal-title":"J Immunol"},{"key":"2661_CR24","doi-asserted-by":"crossref","first-page":"v3","DOI":"10.1093\/rheumatology\/kes113","volume":"51","author":"Ernest Choy","year":"2012","unstructured":"Choy Ernest (2012) Understanding the dynamics: pathways involved in the pathogenesis of rheumatoid arthritis. Rheumatology 51:v3\u2013v11","journal-title":"Rheumatology"},{"key":"2661_CR25","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1177\/1759720X13485328","volume":"5","author":"H Kellner","year":"2013","unstructured":"Kellner H (2013) Targeting interleukin-17 in patients with active rheumatoid arthritis: rationale and clinical potential. Ther Adv Musculoskelet Dis 5:141\u2013152","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"2661_CR26","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/nri2711","volume":"10","author":"M Saraiva","year":"2010","unstructured":"Saraiva M, O\u2019Garra A (2010) The regulation of IL-10 production by immune cells. Nat Rev Immunol 10:170\u2013181","journal-title":"Nat Rev Immunol"},{"key":"2661_CR27","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/art.1780310302","volume":"31","author":"FC Arnett","year":"1988","unstructured":"Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315\u2013324","journal-title":"Arthritis Rheum"},{"key":"2661_CR28","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1046\/j.1365-2249.1996.d01-828.x","volume":"106","author":"H Schulze-Koops","year":"1996","unstructured":"Schulze-Koops H, Lipsky PE, Kavanaugh AF, Davis LS (1996) Persistent reduction in IL-6 mRNA in peripheral blood mononuclear cells of patients with rheumatoid arthritis after treatment with a monoclonal antibody to CD54 (ICAM-1). Clin Exp Immunol 106:190\u2013196","journal-title":"Clin Exp Immunol"},{"issue":"7","key":"2661_CR29","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1016\/j.molimm.2006.07.300","volume":"44","author":"V Arora","year":"2007","unstructured":"Arora V, Mondal AM, Grover R, Kumar A, Chattopadhyay P, Das N (2007) Modulation\u00a0of\u00a0CR1 transcript in systemic lupus erythematosus (SLE) by\u00a0IFN-gamma and\u00a0immune\u00a0complex. Mol Immunol 44(7):1722\u20131728","journal-title":"Mol Immunol"},{"key":"2661_CR30","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1002\/art.23721","volume":"59","author":"KG Saag","year":"2008","unstructured":"Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR et al (2008) American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 59:762\u2013784","journal-title":"Arthritis Rheum"},{"key":"2661_CR31","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1590\/S0482-50042011000500009","volume":"51","author":"AK Piccoli","year":"2011","unstructured":"Piccoli AK, Alegretti AP, Schneider L, Lora PS, Xavier RM (2011) Expression of complement regulatory proteins CD55, CD59, CD35, and CD46 in rheumatoid arthritis. Rev Bras Reumatol 51:503\u2013510","journal-title":"Rev Bras Reumatol"},{"key":"2661_CR32","doi-asserted-by":"crossref","first-page":"316","DOI":"10.3109\/03009749409099280","volume":"23","author":"ME Davies","year":"1994","unstructured":"Davies ME, Horner A, Loveland BE, McKenzie IF (1994) Upregulation of complement regulators MCP (CD46), DAF (CD55) and protectin (CD59) in arthritic joint disease. Scand J Rheumatol 23:316\u2013321","journal-title":"Scand J Rheumatol"},{"key":"2661_CR33","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1046\/j.1365-2249.2002.01924.x","volume":"129","author":"CL Harris","year":"2002","unstructured":"Harris CL, Williams AS, Linton SM, Morgan BP (2002) Coupling complement regulators to immunoglobulin domains generates effective anti-complement reagents with extended half -life in vivo. Clin Exp Immunol 129:198\u2013207","journal-title":"Clin Exp Immunol"},{"key":"2661_CR34","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1002\/art.1780380106","volume":"38","author":"JS Smolen","year":"1995","unstructured":"Smolen JS, Breedveld FC, Eberl G, Jones I, Leeming M, Wylie GL et al (1995) Validity and reliability of the twenty-eight-joint count for the assessment of rheumatoid arthritis activity. Arthritis Rheum 38:38\u201343","journal-title":"Arthritis Rheum"},{"key":"2661_CR35","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1172\/JCI108708","volume":"59","author":"UE Nydegger","year":"1977","unstructured":"Nydegger UE, Zubler RH, Gabay R, Joliat G, Karagevrekis CH, Lambert PH, Miescher PA (1977) Circulating complement breakdown products in patients with rheumatoid arthritis. Correlation between plasma C3d, circulating immune complexes, and clinical activity. J Clin Invest 59:862\u2013868","journal-title":"J Clin Invest"},{"key":"2661_CR36","first-page":"747","volume":"48","author":"RK Mallya","year":"1982","unstructured":"Mallya RK, Vergani D, Tee DE, Bevis L, de Beer FC, Berry H, Hamilton ED, Mace BE, Pepys MB (1982) Correlation in rheumatoid arthritis of concentrations of plasma C3d, serum rheumatoid factor, immune complexes and C-reactive protein with each other and with clinical features of disease activity. Clin Exp Immunol 48:747\u2013753","journal-title":"Clin Exp Immunol"},{"key":"2661_CR37","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1136\/ard.48.4.302","volume":"48","author":"VA Makinde","year":"1989","unstructured":"Makinde VA, Senaldi G, Jawad AS, Berry H, Vergani D (1989) Reflection of disease activity in rheumatoid arthritis by indices of activation of the classical complement pathway. Ann Rheum Dis 48:302\u2013306","journal-title":"Ann Rheum Dis"},{"key":"2661_CR38","first-page":"433","volume":"10","author":"A Corvetta","year":"1992","unstructured":"Corvetta A, Pomponio G, Rinaldi N, Luchetti MM, Di Loreto C, Stramazzotti D (1992) Terminal complement complex in synovial tissue from patients affected by rheumatoid arthritis, osteoarthritis and acute joint trauma. Clin Exp Rheumatol 10:433\u2013438","journal-title":"Clin Exp Rheumatol"},{"key":"2661_CR39","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1136\/ard.55.12.888","volume":"55","author":"YT Konttinen","year":"1996","unstructured":"Konttinen YT, Ceponis A, Meri S, Vuorikoski A, Kortekangas P, Sorsa T, Sukura A, Santavirta S (1996) Complement in acute and chronic arthritides: assessment of C3c, C9, and protectin (CD59) in synovial membrane. Ann Rheum Dis 55:888\u2013894","journal-title":"Ann Rheum Dis"},{"key":"2661_CR40","first-page":"1028","volume":"13","author":"ME Sanders","year":"1986","unstructured":"Sanders ME, Kopicky JA, Wigley FM, Shin ML, Frank MM, Joiner KA (1986) Membrane attack complex of complement in rheumatoid synovial tissue demonstrated by immunofluorescent microscopy. J Rheumatol 13:1028\u20131034","journal-title":"J Rheumatol"},{"key":"2661_CR41","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1046\/j.1365-2249.1998.00660.x","volume":"113","author":"J Nasu","year":"1998","unstructured":"Nasu J, Mizuno M, Uesu T, Takeuchi K, Inaba T et al (1998) Cytokine-stimulated release of decay-accelerating factor (DAF; CD55) from HT-29 human intestinal epithelial cells. Clin Exp Immunol 113:379\u2013385","journal-title":"Clin Exp Immunol"},{"key":"2661_CR42","doi-asserted-by":"crossref","unstructured":"Das N, Biswas B, Arora V, Kumar U, Kumar A (2013) Effect of immune complexes and cytokines on expression and modulation of neutrophil complement regulatory proteins in SLE. Frontiers Immunol. Suppl doi: 10.3389\/conf.fimmu.2013.02.00208","DOI":"10.3389\/conf.fimmu.2013.02.00208"},{"key":"2661_CR43","doi-asserted-by":"crossref","first-page":"4431","DOI":"10.4049\/jimmunol.1202242","volume":"191","author":"H Suzuki","year":"2013","unstructured":"Suzuki H, Lasbury ME, Fan L, Vittal R, Mickler EA et al (2013) Role of complement activation in obliterative bronchiolitis post-lung transplantation. J Immunol 191:4431\u20134439","journal-title":"J Immunol"},{"key":"2661_CR44","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1076\/ceyr.23.2.86.5478","volume":"23","author":"ET Cocuzzi","year":"2001","unstructured":"Cocuzzi ET, Bardenstein DS, Stavitsky A, Sundarraj N, Medof ME (2001) Upregulation of DAF (CD55) on orbital fibroblasts by cytokines. Differential effects of TNF-beta and TNF-alpha. Curr Eye Res 23:86\u201392","journal-title":"Curr Eye Res"},{"key":"2661_CR45","author":"Y Du","year":"2013","unstructured":"Du Y, Deng L, Li Y, Gan L, Wang Y, Shi G (2013) Decreased PERP expression on peripheral blood mononuclear cells from patient with rheumatoid arthritis negatively correlates with disease activity. Clin Dev Immunol. doi: 10.1155\/2013\/256462","journal-title":"Clin Dev Immunol."},{"key":"2661_CR46","doi-asserted-by":"crossref","first-page":"118","DOI":"10.3109\/03009740903170823","volume":"39","author":"T Alanara","year":"2010","unstructured":"Alanara T, Karstila K, Moilanen T, Silvennoinen O, Isomaki P (2010) Expression of IL-10 family cytokines in rheumatoid arthritis elevated levels of IL-19 in the joints. Scand J Rheumatol 39:118\u2013126","journal-title":"Scand J Rheumatol"},{"key":"2661_CR47","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1002\/art.21749","volume":"54","author":"BW Kirkham","year":"2006","unstructured":"Kirkham BW, Lassere MN, Edmonds JP, Juhasz KM, Bird PA, Lee CS, Shnier R, Portek IJ (2006) Synovial membrane cytokine expression is predictive of joint damage progression in rheumatoid arthritis: a two-year prospective study (the DAMAGE study cohort). Arthritis Rheum 54:1122\u20131131","journal-title":"Arthritis Rheum"},{"key":"2661_CR48","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1155\/2010\/158514","volume":"2010","author":"PW Meyer","year":"2010","unstructured":"Meyer PW, Hodkinson B, Ally M, Musenge E, Wadee AA, Fickl H, Tikly M, Anderson R (2010) Circulating cytokine profiles and their relationships with autoantibodies, acute phase reactants, and disease activity in patients with rheumatoid arthritis. Mediators Inflamm 2010:154\u2013158","journal-title":"Mediators Inflamm"},{"key":"2661_CR49","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/j.1744-313X.2010.00913.x","volume":"37","author":"A Paradowska-Gorycka","year":"2010","unstructured":"Paradowska-Gorycka A, Trefler J, Maciejewska-Stelmach J, Cki JKL (2010) Interleukin-10 gene promoter polymorphism in Polish rheumatoid arthritis patients. Int J Immunogenet 37:225\u2013231","journal-title":"Int J Immunogenet"},{"key":"2661_CR50","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.4049\/jimmunol.161.3.1568","volume":"161","author":"J Weyenbergh Van","year":"1998","unstructured":"Van Weyenbergh J, Lipinski P, Abadie A et al (1998) Antagonistic action of IFN-\u03b1, IFN-g on high affinity Fcg receptor expression in healthy controls and multiple sclerosis patients. J Immunol 161:1568\u20131574","journal-title":"J Immunol"},{"key":"2661_CR51","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0065-2776(07)96002-2","volume":"96","author":"JR Schoenborn","year":"2007","unstructured":"Schoenborn JR, Wilson CB (2007) Regulation of interferon-gamma during innate and adaptive immune responses. Adv Immunol 96:41\u2013101","journal-title":"Adv Immunol"},{"key":"2661_CR52","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.immuni.2011.03.018","volume":"34","author":"A Chaudhry","year":"2011","unstructured":"Chaudhry A, Samstein RM, Treuting P, Liang Y, Pils MC, Heinrich JM, Jack RS, Wunderlich FT et al (2011) Interleukin-10 signaling in regulatory T cells is required for suppression of Th17 cell-mediated inflammation. Immunity 34:566\u2013578","journal-title":"Immunity"}],"container-title":["Molecular and Cellular Biochemistry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11010-016-2661-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11010-016-2661-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11010-016-2661-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T00:12:01Z","timestamp":1692231121000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11010-016-2661-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2,23]]},"references-count":52,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["2661"],"URL":"https:\/\/doi.org\/10.1007\/s11010-016-2661-x","relation":{},"ISSN":["0300-8177","1573-4919"],"issn-type":[{"type":"print","value":"0300-8177"},{"type":"electronic","value":"1573-4919"}],"subject":[],"published":{"date-parts":[[2016,2,23]]}}}